BIIB
Biogen Inc.
215.50$
-1.6%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +10.9% | +6.4% | +7.2% | +9.6% | +6.9% | -6.5% | -18.3% | -7.4% | -3.3% | -1.6% | +1.4% | |
| – | +5.9% | +15.5% | +13.7% | +11.4% | +7.7% | -7.7% | +16.9% | +8.0% | +11.2% | -8.8% | +25.4% | |
| – | +11.6% | +5.2% | +6.3% | +9.3% | +6.8% | -6.3% | -23.8% | -11.0% | -7.5% | +0.9% | -6.1% | |
| – | +6.3% | -2.0% | +20.3% | +14.2% | +2.2% | +63.5% | -24.9% | -23.6% | +4.1% | -7.9% | -21.5% | |
| – | -6.3% | -8.0% | +1.0% | +8.5% | +12.9% | +5.4% | +7.4% | -8.8% | +3.2% | -4.6% | +4.9% | |
| – | +1.6% | +5.0% | +8.9% | +8.5% | -6.4% | +31.0% | -13.7% | -17.7% | +4.0% | -6.3% | +3.3% | |
| – | +23.1% | +5.3% | +3.8% | +10.2% | +19.6% | -34.8% | -39.2% | +3.5% | -27.4% | +18.7% | -24.6% | |
| – | +223.7% | +172.3% | -3.5% | -20.0% | -6.6% | +18.7% | +14.0% | -2.8% | +0.1% | +1.4% | -1.7% | |
| – | +20.9% | +3.7% | +4.0% | +15.0% | +19.4% | -28.3% | -64.8% | +101.9% | -63.9% | +47.0% | -26.5% | |
| – | +17.3% | +6.5% | +98.7% | -42.0% | -18.8% | -14.3% | -94.7% | +1,105.3% | -78.6% | +102.4% | -60.5% | |
| – | +20.9% | +4.4% | -31.4% | +74.5% | +32.9% | -32.1% | -61.1% | +95.8% | -61.9% | +40.6% | -20.8% | |
| – | +21.9% | +13.0% | +4.1% | +6.2% | +10.3% | -34.0% | -23.2% | -9.9% | -32.8% | +26.0% | +3.5% |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.